Ionis Pharmaceuticals, Inc.
IONS
Rang in Aktien
#2583
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Aktienkurs
$44.35
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$7.37B
Veränderung (1 Tag)
3.28%
Veränderung (1 Jahr)
-39.70%
Land
US
Handel Ionis Pharmaceuticals, Inc. (IONS)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Ionis Pharmaceuticals, Inc. (IONS)
Anzahl der ausstehenden Aktien zum June 2026: 165.42M
Laut den neuesten Finanzberichten und dem Aktienkurs von Ionis Pharmaceuticals, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 165.42M. Am Ende von December 2023 hatte das Unternehmen 143.00M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Ionis Pharmaceuticals, Inc. (IONS) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 165.42M | 10.64% |
| 2024 | 149.51M | 4.56% |
| 2023 | 143.00M | 0.81% |
| 2022 | 141.85M | 0.59% |
| 2021 | 141.02M | 1.01% |
| 2020 | 139.61M | -0.28% |
| 2019 | 140.00M | 5.80% |
| 2018 | 132.32M | 6.70% |
| 2017 | 124.02M | 2.66% |
| 2016 | 120.80M | 1.26% |
| 2015 | 119.29M | 1.36% |
| 2014 | 117.69M | 6.51% |
| 2013 | 110.50M | 9.87% |
| 2012 | 100.58M | 0.92% |
| 2011 | 99.66M | 0.52% |
| 2010 | 99.14M | 1.05% |
| 2009 | 98.11M | 3.75% |
| 2008 | 94.57M | 12.93% |
| 2007 | 83.74M | 12.69% |
| 2006 | 74.31M | 18.18% |
| 2005 | 62.88M | 11.01% |
| 2004 | 56.64M | 2.13% |
| 2003 | 55.46M | 1.80% |
| 2002 | 54.48M | 23.51% |
| 2001 | 44.11M | 19.14% |
| 2000 | 37.02M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 53.49% |
US
|
|
| 396.00M | 139.39% |
US
|
|
| 478.91M | 189.51% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.41% |
NL
|
